



2014-09-01

PRESS RELEASE

Anders Blom new Executive Vice President in Oasmia

The pharmaceutical company Oasmia Pharmaceutical announced today that Anders Blom has been appointed Executive Vice President in Oasmia. He is succeeding Hans Sundin who is nominated to become a new member of the Board of Directors of Oasmia.

Anders has more than 15 years of experience from international strategic business development and finance at Q-Med and Pharmacia. He has a Master of Business Administration degree from Uppsala University and he is currently CEO of Nexttobe AB where he will continue to have certain responsibilities.

As a new Executive Vice President, Anders will primarily focus on Oasmia's business development. He will be succeeding Hans Sundin who leaves his position and who is nominated to become a new member of the Board of Oasmia Pharmaceutical AB. In addition to the task of being a Board member, Hans will also be participating in the company's strategic production project and quality issues from a general perspective.

"I am very happy to welcome Anders to the company. His experience and knowledge will be most valuable at this stage of development of the company. At the same time it is my conviction that the future work of Hans as a Board member will contribute as an excellent and fundamental complement to the existing competence within the Board," the CEO of the company, Julian Aleksov, commented this reorganization.

Anders' new employment starts on October 1, 2014.

For more information, please contact:

Mikael Widell, Vice President Communications

Mobile: +46 70 311 99 60

E-mail: mikael.widell@oasmia.com

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).

Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia

“Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 09.00, CET on September 1, 2014.”